Any current/future new fundraising through debt or equity?

The company anticipates a total capital expenditure of roughly INR200 crores for the full year, mainly funded through internal accruals and partly through term loans. There is no explicit mention of new fundraising through equity in the transcript. The company completed a buyback of 665,000 equity shares at INR900 per share in September 2024. Overall, the company appears to rely mostly on internal accruals and some term loans for funding its ongoing capex and growth projects. No specific plans for fresh debt or equity issuance were disclosed during the call.

Any current/future capex/capital investment/strategic investment?

The greenfield Specialty Chemicals plant at Saykha is complete, with trials started; main plant trials to begin by mid-to-end November 2024. Planned capex for the current year is roughly INR200 crores, funded mainly internally with some term loans. Ongoing capex includes capacity expansion, backward integration, and new product launches; around INR90 crores spent in H1 FY25. The Saykha greenfield project expected to come on stream by Q3 or Q4 FY25, moving roughly INR300 crores from CWIP to fixed assets. Small brownfield expansions are in progress for cardio protectants and anti-diarrhe

Future growth expectations in sales/revenue/volumes?

FY '25 sales expected to be flattish compared to FY '24 due to lackluster demand and negative rate variance despite volume growth. FY '26 anticipated as a turnaround year driven by ramp-up and streamlined operations of the Salicylic Acid plant. Formulation business has strong order book (~$12 million) and export potential; growth expected in coming 2-3 quarters. Specialty Chemicals plant at Saykha to start production trials by November; long-term EBITDA potential of ~INR40 crores. Revised sales guidance now INR3,500 crores to INR4,000 crores for next 2-3 years, down from earlier INR4,200 crore

Future growth expectations in earnings/operating earnings/profits/EPS?

Aarti Drugs Limited targets long-term EBITDA margins of 14.5% to 15.5%, aiming to restore historical profitability levels. Current pricing levels have led to revised revenue potential of INR 3,500 to 4,000 crores in the medium term (previously INR 4,200 to 4,500 crores). FY '25 is expected to be flattish in revenue due to subdued demand and pricing but FY '26 is seen as a turnaround year driven by ramp-up of Salicylic Acid capacity and improved operating leverage. Specialty Chemicals plant at Saykha to contribute approximately INR 40 crores to EBITDA in the longer term. Increased produ

Current/ Expected Orderbook/ Pending Orders?

The formulation business has a strong order book of over $12 million as of the September quarter. Despite nominal sales of $2 million to $2.5 million in the September quarter, the robust order book indicates a significant export potential. The Specialty Chemicals plant at Saykha is starting trials in November, expected to contribute long-term EBITDA of around INR 40 crores. Upcoming production from the Specialty Chemicals plant will mostly serve captive consumption with some volume for external sales. Export markets have started showing demand uptick, indicating potential growth in order inflo

Aarti Drugs LtdQ2 FY25Pharmaceuticals & Biotechnology

Aarti Drugs Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹449P/E: 21.3Market Cap: ₹4.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 4

FY '25 sales expected to be flattish compared to FY '24 due to lackluster demand and negative rate variance despite volume growth.
FY '26 anticipated as a turnaround year driven by ramp-up and streamlined operations of the Salicylic Acid plant.
Formulation business has strong order book (~$12 million) and export potential; growth expected in coming 2-3 quarters.
Specialty Chemicals plant at Saykha to start production trials by November; long-term EBITDA potential of ~INR40 crores.
Revised sales guidance now INR3,500 crores to INR4,000 crores for next 2-3 years, down from earlier INR4,200 crores-4,500 crores guidance, largely due to current API pricing.
Metformin capacity planned to scale from current ~1,350-1,400 tons/month to 1,700-1,800 tons/month short term, and up to 3,000 tons/month longer term.
API segment volume utilization at 78%, with scope for growth via capacity expansions and new products.
Overall long-term EBITDA margin target around 14.5%-15.5%.

Margin guidance

Category 3

Aarti Drugs Limited targets long-term EBITDA margins of 14.5% to 15.5%, aiming to restore historical profitability levels.
Current pricing levels have led to revised revenue potential of INR 3,500 to 4,000 crores in the medium term (previously INR 4,200 to 4,500 crores).
FY '25 is expected to be flattish in revenue due to subdued demand and pricing but FY '26 is seen as a turnaround year driven by ramp-up of Salicylic Acid capacity and improved operating leverage.
Specialty Chemicals plant at Saykha to contribute approximately INR 40 crores to EBITDA in the longer term.
Increased product registrations and export orders in formulation business with a strong order book (~$12 million) indicate growth prospects.
Capex largely complete by FY '25 end; further expansions planned mainly through brownfield projects to support growth beyond INR 3,500 crores turnover by FY '27.
Ramp-up of metformin and other high-margin products is expected to improve earnings visibility in coming quarters.

See what Aarti Drugs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company anticipates a total capital expenditure of roughly INR200 crores for the full year, mainly funded through internal accruals and partly through term loans.
There is no explicit mention of new fundraising through equity in the transcript.
The company completed a buyback of 665,000 equity shares at INR900 per share in September 2024.
Overall, the company appears to rely mostly on internal accruals and some term loans for funding its ongoing capex and growth projects.
No specific plans for fresh debt or equity issuance were disclosed during the call.

Order book

Yes

The formulation business has a strong order book of over $12 million as of the September quarter.
Despite nominal sales of $2 million to $2.5 million in the September quarter, the robust order book indicates a significant export potential.
The Specialty Chemicals plant at Saykha is starting trials in November, expected to contribute long-term EBITDA of around INR 40 crores.
Upcoming production from the Specialty Chemicals plant will mostly serve captive consumption with some volume for external sales.
Export markets have started showing demand uptick, indicating potential growth in order inflows.
Overall, Aarti Drugs Limited anticipates picking up formulation business growth over the next 2 to 3 quarters supported by a strong order pipeline.

See what Aarti Drugs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The greenfield Specialty Chemicals plant at Saykha is complete, with trials started; main plant trials to begin by mid-to-end November 2024.
Planned capex for the current year is roughly INR200 crores, funded mainly internally with some term loans.
Ongoing capex includes capacity expansion, backward integration, and new product launches; around INR90 crores spent in H1 FY25.
The Saykha greenfield project expected to come on stream by Q3 or Q4 FY25, moving roughly INR300 crores from CWIP to fixed assets.
Small brownfield expansions are in progress for cardio protectants and anti-diarrheal products, with anti-diarrheal facility starting soon.
Future capex plans exist but are still on paper pending product finalization; FY27 turnover expected between INR3,500-4,000 crores.
Capacity expansion plans include scaling metformin up from current 1,350-1,400 tons/month to 1,700-1,800 tons/month post land acquisition.
Focus on improving operational efficiencies and power cost via renewable energy investments.

Track Aarti Drugs Ltd — get its next earnings analysis in your feed

How does Aarti Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAarti Drugs Ltd

Rev 4Mar 3

See where Aarti Drugs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Aarti Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Aarti Drugs Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Aarti Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →